Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis

Enrique A. Mesri, Lucas E. Cavallin, Brittany M. Ashlock, Howard J. Leung, Qi Ma, Pascal J. Goldschmidt-Clermont

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Kaposi's sarcoma herpesvirus or human herpesvirus-8 (KSHV/HHV-8) is the etiological agent of Kaposi's sarcoma (KS), an AIDS-defining angioproliferative neoplasm that continues to be a major global health problem and, of primary effusion lymphoma (PEL), a rare incurable B-cell lymphoma. This review describes the research from our laboratory and its collaborators to uncover molecular mechanisms of viral oncogenesis in order to develop new pathogenesis-based therapies to the KSHV-induced AIDS malignancies KS and PEL they include the discovery of the viral angiogenic oncogene G protein-coupled receptor (vGPCR), the development of mouse models of KSHV and oxidative stress-induced KS, the identification of the role of Rac1-induced ROS in viral oncogenesis of KS and the development of novel therapeutic approaches able to target both latent and lytic oncogenic KSHV infection.

Original languageEnglish (US)
Pages (from-to)159-165
Number of pages7
JournalImmunologic Research
Volume57
Issue number1-3
DOIs
StatePublished - Dec 1 2013

Keywords

  • AIDS-associated malignancies
  • Angiogenesis
  • Animal models of cancer
  • Antivirals
  • Human herpesvirus-8
  • Targeted therapies

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis'. Together they form a unique fingerprint.

  • Cite this

    Mesri, E. A., Cavallin, L. E., Ashlock, B. M., Leung, H. J., Ma, Q., & Goldschmidt-Clermont, P. J. (2013). Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis. Immunologic Research, 57(1-3), 159-165. https://doi.org/10.1007/s12026-013-8458-z